Published in J Biol Chem on February 04, 2014
Mechanism of quinolone action and resistance. Biochemistry (2014) 1.34
In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Antimicrob Agents Chemother (2016) 1.01
Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci (2015) 1.00
Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2016) 0.94
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (2015) 0.87
Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. ACS Chem Biol (2014) 0.83
Bactericidal activities of GM flax seedcake extract on pathogenic bacteria clinical strains. BMC Biotechnol (2014) 0.77
Characterization and Genomic Analysis of Quinolone-Resistant Delftia sp. 670 Isolated from a Patient Who Died from Severe Pneumonia. Curr Microbiol (2015) 0.77
Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex. Acta Crystallogr D Struct Biol (2016) 0.76
Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions. Int J Med Sci (2015) 0.75
Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida. Antimicrob Agents Chemother (2017) 0.75
Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic Acids Res (2016) 0.75
Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. Open Biol (2016) 0.75
The global regulatory protein CRP controls multifactorial fluoroquinolone susceptibility in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother (2017) 0.75
Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase. PLoS One (2017) 0.75
Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47
Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A (1977) 18.37
Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A (1977) 14.75
DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem (2001) 12.53
Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol (2002) 11.79
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS. J Bacteriol (1965) 9.57
Genetic systems for mycobacteria. Methods Enzymol (1991) 7.50
New topoisomerase essential for chromosome segregation in E. coli. Cell (1990) 7.19
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition. Proc Natl Acad Sci U S A (1981) 5.60
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
Gene splicing by overlap extension. Methods Enzymol (1993) 4.59
Crystal structure of the breakage-reunion domain of DNA gyrase. Nature (1997) 4.10
DNA gyrase action involves the introduction of transient double-strand breaks into DNA. Proc Natl Acad Sci U S A (1980) 3.87
Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature (2010) 3.58
DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol (1979) 3.43
lon transcriptional regulation of genes necessary for capsular polysaccharide synthesis in Escherichia coli K-12. J Bacteriol (1984) 3.26
Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem (1983) 3.05
Quinolone-mediated bacterial death. Antimicrob Agents Chemother (2007) 2.94
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature (2007) 2.79
Formation and resolution of DNA catenanes by DNA gyrase. Cell (1980) 2.68
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis (2000) 2.35
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother (1998) 2.35
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother (1999) 2.16
Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol (2009) 2.05
Phage P1 mutants with altered transducing abilities for Escherichia coli. Virology (1974) 1.91
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother (2000) 1.69
Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro. J Biol Chem (1994) 1.58
The complex of DNA gyrase and quinolone drugs on DNA forms a barrier to the T7 DNA polymerase replication complex. J Mol Biol (2000) 1.50
Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One (2010) 1.45
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol (2010) 1.45
DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex. J Biol Chem (2000) 1.43
DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry (1996) 1.31
Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother (2009) 1.24
The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem (1998) 1.23
The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions. Biochemistry (2002) 1.13
Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo. Mol Microbiol (2005) 1.11
A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function. Nucleic Acids Res (2010) 1.09
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res (2013) 1.04
Interactions between DNA helicases and frozen topoisomerase IV-quinolone-DNA ternary complexes. J Biol Chem (1999) 1.03
Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry (2011) 1.01
In vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus. Antimicrob Agents Chemother (2009) 0.98
The use of divalent metal ions by type II topoisomerases. Metallomics (2010) 0.98
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother (2009) 0.92
Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA. Antimicrob Agents Chemother (2012) 0.90
Phenotypic and molecular characterization of Acinetobacter clinical isolates obtained from inmates of California correctional facilities. J Clin Microbiol (2011) 0.89
Lon protease is essential for paradoxical survival of Escherichia coli exposed to high concentrations of quinolone. Antimicrob Agents Chemother (2009) 0.83
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg Med Chem (2009) 0.80
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 12.53
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
Evolutionary relationships and structural mechanisms of AAA+ proteins. Annu Rev Biophys Biomol Struct (2006) 4.74
A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A (2002) 4.16
DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys (2008) 3.50
Running in reverse: the structural basis for translocation polarity in hexameric helicases. Cell (2009) 3.38
Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct (2004) 3.37
Structure of the Rho transcription terminator: mechanism of mRNA recognition and helicase loading. Cell (2003) 3.00
DNA replication initiation: mechanisms and regulation in bacteria. Nat Rev Microbiol (2007) 2.96
Quinolone-mediated bacterial death. Antimicrob Agents Chemother (2007) 2.94
The structural basis for MCM2-7 helicase activation by GINS and Cdc45. Nat Struct Mol Biol (2011) 2.93
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature (2007) 2.79
Structural basis for ATP-dependent DnaA assembly and replication-origin remodeling. Nat Struct Mol Biol (2006) 2.73
The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol (2009) 2.69
All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol (2011) 2.66
Activation of the DExD/H-box protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator InsP6 is required for mRNA export. Nat Cell Biol (2006) 2.58
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
Mutant selection window hypothesis updated. Clin Infect Dis (2007) 2.34
Identifying Mycobacterium tuberculosis complex strain families using spoligotypes. Infect Genet Evol (2006) 2.28
Identification, function and structure of the mycobacterial sulfotransferase that initiates sulfolipid-1 biosynthesis. Nat Struct Mol Biol (2004) 2.25
Replication origin recognition and deformation by a heterodimeric archaeal Orc1 complex. Science (2007) 2.10
Contribution of oxidative damage to antimicrobial lethality. Antimicrob Agents Chemother (2009) 2.09
The structural basis for substrate specificity in DNA topoisomerase IV. J Mol Biol (2005) 2.08
Fluoroquinolones: action and resistance. Curr Top Med Chem (2003) 2.04
Structure and function of the conserved core of histone deposition protein Asf1. Curr Biol (2003) 2.02
The structure of bacterial DnaA: implications for general mechanisms underlying DNA replication initiation. EMBO J (2002) 1.98
Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis (2002) 1.96
Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep (2013) 1.96
The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold. Proc Natl Acad Sci U S A (2004) 1.93
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet (2013) 1.93
In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.92
The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Dev (2004) 1.90
The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol (2012) 1.87
Nucleotide-dependent conformational changes in the DnaA-like core of the origin recognition complex. Nat Struct Mol Biol (2006) 1.80
Identification of residues in yeast Spo11p critical for meiotic DNA double-strand break formation. Mol Cell Biol (2002) 1.77
Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol (2006) 1.75
Quinolones: action and resistance updated. Curr Top Med Chem (2009) 1.73
Suite of three protein crystallography beamlines with single superconducting bend magnet as the source. J Synchrotron Radiat (2004) 1.70
A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export. Nature (2011) 1.70
Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother (2010) 1.69
A microfluidic device for kinetic optimization of protein crystallization and in situ structure determination. J Am Chem Soc (2006) 1.65
Binding mechanism of metal⋅NTP substrates and stringent-response alarmones to bacterial DnaG-type primases. Structure (2012) 1.64
The N-terminal domain of Nup159 forms a beta-propeller that functions in mRNA export by tethering the helicase Dbp5 to the nuclear pore. Mol Cell (2004) 1.59
Molecular epidemiology of Mycobacterium tuberculosis in a South African community with high HIV prevalence. J Infect Dis (2009) 1.59
A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature (2010) 1.59
Application of sensitive and specific molecular methods to uncover global dissemination of the major RDRio Sublineage of the Latin American-Mediterranean Mycobacterium tuberculosis spoligotype family. J Clin Microbiol (2008) 1.59
Structural insights into RNA-dependent ring closure and ATPase activation by the Rho termination factor. Cell (2006) 1.58
Crosstalk between primase subunits can act to regulate primer synthesis in trans. Mol Cell (2005) 1.57
The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence. Infect Immun (2008) 1.55
DNA stretching by bacterial initiators promotes replication origin opening. Nature (2011) 1.55
Structural synergy and molecular crosstalk between bacterial helicase loaders and replication initiators. Cell (2008) 1.51
The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology (2010) 1.47
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother (2002) 1.46
Discovery of a novel Mycobacterium tuberculosis lineage that is a major cause of tuberculosis in Rio de Janeiro, Brazil. J Clin Microbiol (2007) 1.45
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A (2003) 1.44
The nuts and bolts of ring-translocase structure and mechanism. Curr Opin Struct Biol (2011) 1.44
Identification of a DNA primase template tracking site redefines the geometry of primer synthesis. Nat Struct Mol Biol (2008) 1.42
The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.41
Escherichia coli condensin MukB stimulates topoisomerase IV activity by a direct physical interaction. Proc Natl Acad Sci U S A (2010) 1.41
Identification and evolution of an IS6110 low-copy-number Mycobacterium tuberculosis cluster. J Infect Dis (2002) 1.35
Function and structure of a prokaryotic formylglycine-generating enzyme. J Biol Chem (2008) 1.35
Structure of the yeast histone H3-ASF1 interaction: implications for chaperone mechanism, species-specific interactions, and epigenetics. BMC Struct Biol (2006) 1.34
Mechanism of quinolone action and resistance. Biochemistry (2014) 1.34
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2009) 1.33
Crystal structure and nonhomologous end-joining function of the ligase component of Mycobacterium DNA ligase D. J Biol Chem (2006) 1.31
Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. J Clin Microbiol (2010) 1.30
AAA+ ATPases in the initiation of DNA replication. Crit Rev Biochem Mol Biol (2008) 1.29
Mechanisms for initiating cellular DNA replication. Annu Rev Biochem (2013) 1.28
THAP proteins target specific DNA sites through bipartite recognition of adjacent major and minor grooves. Nat Struct Mol Biol (2009) 1.27
The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis (2006) 1.25
The MukF subunit of Escherichia coli condensin: architecture and functional relationship to kleisins. EMBO J (2005) 1.24
Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents (2004) 1.22
Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob Agents Chemother (2006) 1.22
ATP-dependent conformational dynamics underlie the functional asymmetry of the replicative helicase from a minimalist eukaryote. Proc Natl Acad Sci U S A (2012) 1.21
Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother (2004) 1.20
Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob Agents Chemother (2005) 1.19
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.19
A unified anti-mutant dosing strategy. J Antimicrob Chemother (2008) 1.19
Structure of the topoisomerase VI-B subunit: implications for type II topoisomerase mechanism and evolution. EMBO J (2003) 1.18
Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob Agents Chemother (2006) 1.18
Structural and computational characterization of the SHV-1 beta-lactamase-beta-lactamase inhibitor protein interface. J Biol Chem (2006) 1.16
The bacterial DnaC helicase loader is a DnaB ring breaker. Cell (2013) 1.14
Inhibitors of reactive oxygen species accumulation delay and/or reduce the lethality of several antistaphylococcal agents. Antimicrob Agents Chemother (2012) 1.13
Regulation of bacterial priming and daughter strand synthesis through helicase-primase interactions. Nucleic Acids Res (2006) 1.13
Simultaneous identification of mycobacterial isolates to the species level and determination of tuberculosis drug resistance by PCR followed by electrospray ionization mass spectrometry. J Clin Microbiol (2010) 1.12
The "GyrA-box" is required for the ability of DNA gyrase to wrap DNA and catalyze the supercoiling reaction. J Biol Chem (2005) 1.11
Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci (2007) 1.11
Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother (2003) 1.10
Origin remodeling and opening in bacteria rely on distinct assembly states of the DnaA initiator. J Biol Chem (2010) 1.10